1429176-55-5

Basic information

• Product Name: (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
• Synonyms: (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
• CAS NO: 1429176-55-5
• Molecular Weight: 464.611
• Mol File: 1429176-55-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one(1429176-55-5)
• EPA Substance Registry System: (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one(1429176-55-5)

Safety Data

• Hazardous Substances Data: 1429176-55-5(Hazardous Substances Data)

Upstream product

• 17016-83-0 (4S)-4-isopropyl-1,3-oxazolidin-2-one 
• 1429181-06-5 (S)-3-(2-fluoropyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429183-03-8 {4-[(1S)-1-aminoethyl]phenyl}methanol hydrochloride 
• 1429182-99-9 (S)-3-(2-((S)-1-(4-(hydroxymethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429182-96-6 4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzaldehyde 
• 86732-28-7 cis-hexahydro-2-methylpyrrolo<3,4-c>pyrrole 

Relevant articles and documents

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.